文献速递胰腺与胆道疾病消化道肿瘤与早癌消化内镜

高危个体胰腺癌监测的长期产出

Long-term yield of pancreatic cancer surveillance in high-risk individuals.
PubMed 文献 · Gut · 2021-04-05

2006至2019年前瞻性纳入366例胰腺导管腺癌(PDAC)终生风险≥10%的无症状高危个体,每年接受超声内镜(EUS)和MRI/MRCP监测。突变携带者PDAC累积发生率为9.3%,而突变阴性家族性胰腺癌(FPC)家系为0%(p<0.001)。EUS检出实性病变优于MRI/MRCP,但同期双影像仍难以及时识别可切除病变。

要点

  • 突变携带者PDAC累积发生率为9.3%,突变阴性FPC家系为0%。
  • EUS检出实性病变优于MRI/MRCP(100% vs 22%)。
  • 双影像监测下及时识别可切除病变仍具挑战。

核心结论

  • 已确立的高危突变携带者中PDAC诊断产出可观,但突变阴性FPC家系中不存在。
  • 尽管同时使用两种影像模式,及时识别可切除病变仍具挑战,EUS优于MRI/MRCP。
  • 影像监测总体产出欠佳,明确需要更敏感的诊断标志物包括生物标志物。

研究设计与样本

  • 2006至2019年前瞻性纳入无症状个体,经临床遗传学家评估和基因检测后终生PDAC风险估计≥10%。
  • 每次访视均接受EUS和MRI/MRCP年度监测。
  • 共366人(201例突变阴性FPC家系和165例PDAC易感基因突变携带者;平均年龄54岁,SD 9.9),平均随访63个月(SD 43.2)。

主要发现

  • 10人发生PDAC,其中4例为症状性间期癌,6例接受切除。
  • 突变携带者PDAC累积发生率为9.3%,FPC家系为0%(p<0.001)。
  • PDAC中位生存期为18个月(范围1-32)。
  • 17人(4.6%)接受手术,病理显示6例PDAC(3例T1N0M0)、7例低级别前驱病变、2例<2 cm神经内分泌肿瘤、1例自身免疫性胰腺炎和1例无异常。
  • 无手术相关死亡;EUS检出实性病变多于MRI/MRCP(100% vs 22%,p<0.001),但检出囊性病变少于MRI/MRCP(42% vs 83%,p<0.001)。

临床怎么用

  • 对已确立的PDAC易感基因突变携带者,可考虑年度EUS联合MRI/MRCP监测。
  • 突变阴性FPC家系中影像监测的PDAC诊断产出为零,需权衡监测必要性。
  • EUS对实性病变更敏感,MRI/MRCP对囊性病变更敏感,两者互补但总体及时识别可切除病变仍困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to determine the long-term yield of pancreatic cancer surveillance in hereditary predisposed high-risk individuals. DESIGN: From 2006 to 2019, we prospectively enrolled asymptomatic individuals with an estimated 10% or greater lifetime risk of pancreatic ductal adenocarcinoma (PDAC) after obligatory evaluation by a clinical geneticist and genetic testing, and subjected them to annual surveillance with both endoscopic ultrasonography (EUS) and MRI/cholangiopancreatography (MRI/MRCP) at each visit. RESULTS: 366 individuals (201 mutation-negative familial pancreatic cancer (FPC) kindreds and 165 PDAC susceptibility gene mutation carriers; mean age 54 years, SD 9.9) were followed for 63 months on average (SD 43.2). Ten individuals developed PDAC, of which four presented with a symptomatic interval carcinoma and six underwent resection. The cumulative PDAC incidence was 9.3% in the mutation carriers and 0% in the FPC kindreds (p<0.001). Median PDAC survival was 18 months (range 1-32). Surgery was performed in 17 individuals (4.6%), whose pathology revealed 6 PDACs (3 T1N0M0), 7 low-grade precursor lesions, 2 neuroendocrine tumours <2 cm, 1 autoimmune pancreatitis and in 1 individual no abnormality. There was no surgery-related mortality. EUS detected more solid lesions than MRI/MRCP (100% vs 22%, p<0.001), but less cystic lesions (42% vs 83%, p<0.001). CONCLUSION: The diagnostic yield of PDAC was substantial in established high-risk mutation carriers, but non-existent in the mutation-negative proven FPC kindreds. Nevertheless, timely identification of resectable lesions proved challenging despite the concurrent use of two imaging modalities, with EUS outperforming MRI/MRCP. Overall, surveillance by imaging yields suboptimal results with a clear need for more sensitive diagnostic markers, including biomarkers.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2021. PMID: 33820756. doi:10.1136/gutjnl-2020-323611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。